Our Combination Pan-antigen Cytotoxic Therapy (ComPACTTM) is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product.
ComPACTTM helps unlock the body’s natural defenses and builds upon ImPACT by also providing co-stimulation to enhance T-cell activation and expansion. It has the potential to simplify combination immunotherapy development for oncology patients, as it is designed to deliver the gp96 heat shock protein and a T-cell co-stimulatory fusion protein (OX40L) into a single compound.
ComPACT offers the potential benefits of combination immunotherapy without the need for multiple, independent biologic products.
- Enhances activation of antigen-specific CD8+ T-cells
- Serves as a booster to expand the number of antigen-specific T cells compared to OX40 alone
- Stimulates T-cell memory function to remain effective in the body after treatment, even if the cancer comes back
- Demonstrates less toxicity: The unique identifier and co-stimulatory are supplied at the same time, driving targeted immunity towards the tumor rather than throughout the body